Literature DB >> 25449528

Chemotherapy of WAP-T mouse mammary carcinomas aggravates tumor phenotype and enhances tumor cell dissemination.

Katharina Jannasch1, Florian Wegwitz, Eva Lenfert, Claudia Maenz, Wolfgang Deppert, Frauke Alves.   

Abstract

In this study, the effects of the standard chemotherapy, cyclophosphamide/adriamycin/5-fluorouracil (CAF) on tumor growth, dissemination and recurrence after orthotopic implantation of murine G-2 cells were analyzed in the syngeneic immunocompetent whey acidic protein-T mouse model (Wegwitz et al., PLoS One 2010; 5:e12103; Schulze-Garg et al., Oncogene 2000; 19:1028-37). Single-dose CAF treatment reduced tumor size significantly, but was not able to eradicate all tumor cells, as recurrent tumor growth was observed 4 weeks after CAF treatment. Nine days after CAF treatment, residual tumors showed features of regressive alterations and were composed of mesenchymal-like tumor cells, infiltrating immune cells and some tumor-associated fibroblasts with an intense deposition of collagen. Recurrent tumors were characterized by coagulative necrosis and less tumor cell differentiation compared with untreated tumors, suggesting a more aggressive tumor phenotype. In support, tumor cell dissemination was strongly enhanced in mice that had developed recurrent tumors in comparison with untreated controls, although only few disseminated tumor cells could be detected in various organs 9 days after CAF application. In vitro experiments revealed that CAF treatment of G-2 cells eliminates the vast majority of epithelial tumor cells, whereas tumor cells with a mesenchymal phenotype survive. These results together with the in vivo findings suggest that tumor cells that underwent epithelial-mesenchymal transition and/or exhibit stem-cell-like properties are difficult to eliminate using one round of CAF chemotherapy. The model system described here provides a valuable tool for the characterization of the effects of chemotherapeutic regimens on recurrent tumor growth and on tumor cell dissemination, thereby enabling the development and preclinical evaluation of novel therapeutic strategies to target mammary carcinomas.
© 2014 UICC.

Entities:  

Keywords:  breast cancer; chemotherapy; disseminated tumor cells; recurrent tumor growth; transgenic tumor mouse models

Mesh:

Substances:

Year:  2014        PMID: 25449528     DOI: 10.1002/ijc.29369

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

Review 1.  Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape.

Authors:  Malte Mohme; Sabine Riethdorf; Klaus Pantel
Journal:  Nat Rev Clin Oncol       Date:  2016-09-20       Impact factor: 66.675

2.  Elastic transformation of histological slices allows precise co-registration with microCT data sets for a refined virtual histology approach.

Authors:  Jonas Albers; Angelika Svetlove; Justus Alves; Alexander Kraupner; Francesca di Lillo; M Andrea Markus; Giuliana Tromba; Frauke Alves; Christian Dullin
Journal:  Sci Rep       Date:  2021-05-25       Impact factor: 4.379

3.  Epithelial-mesenchymal plasticity is a decisive feature for the metastatic outgrowth of disseminated WAP-T mouse mammary carcinoma cells.

Authors:  Claudia Maenz; Eva Lenfert; Klaus Pantel; Udo Schumacher; Wolfgang Deppert; Florian Wegwitz
Journal:  BMC Cancer       Date:  2015-03-26       Impact factor: 4.430

4.  An inducible transgenic mouse breast cancer model for the analysis of tumor antigen specific CD8+ T-cell responses.

Authors:  Michael Bruns; Jara Wanger; Olaf Utermöhlen; Wolfgang Deppert
Journal:  Oncotarget       Date:  2015-11-17

5.  HDAC8 suppresses the epithelial phenotype and promotes EMT in chemotherapy-treated basal-like breast cancer.

Authors:  Garyfallia Pantelaiou-Prokaki; Iga Mieczkowska; Geske E Schmidt; Sonja Fritzsche; Evangelos Prokakis; Julia Gallwas; Florian Wegwitz
Journal:  Clin Epigenetics       Date:  2022-01-11       Impact factor: 6.551

6.  Decreased PRC2 activity supports the survival of basal-like breast cancer cells to cytotoxic treatments.

Authors:  Iga K Mieczkowska; Garyfallia Pantelaiou-Prokaki; Evangelos Prokakis; Geske E Schmidt; Lukas C Müller-Kirschbaum; Marcel Werner; Madhobi Sen; Taras Velychko; Katharina Jannasch; Christian Dullin; Joanna Napp; Klaus Pantel; Harriet Wikman; Maria Wiese; Christof M Kramm; Frauke Alves; Florian Wegwitz
Journal:  Cell Death Dis       Date:  2021-11-29       Impact factor: 8.469

7.  Second-Harmonic Generation Imaging Reveals Changes in Breast Tumor Collagen Induced by Neoadjuvant Chemotherapy.

Authors:  Danielle E Desa; Wencheng Wu; Robert M Brown; Edward B Brown; Robert L Hill; Bradley M Turner; Edward B Brown
Journal:  Cancers (Basel)       Date:  2022-02-09       Impact factor: 6.639

8.  ROBO3s: a novel ROBO3 short isoform promoting breast cancer aggressiveness.

Authors:  Marcel Werner; Anna Dyas; Iwan Parfentev; Geske E Schmidt; Iga K Mieczkowska; Lukas C Müller-Kirschbaum; Claudia Müller; Stefan Kalkhof; Oliver Reinhardt; Henning Urlaub; Frauke Alves; Julia Gallwas; Evangelos Prokakis; Florian Wegwitz
Journal:  Cell Death Dis       Date:  2022-09-03       Impact factor: 9.685

9.  T-cell epitope strength in WAP-T mouse mammary carcinomas is an important determinant in PD1/PD-L1 immune checkpoint blockade therapy.

Authors:  Michael Bruns; Jara Wanger; Udo Schumacher; Wolfgang Deppert
Journal:  Oncotarget       Date:  2016-10-04

10.  CEACAM1 controls the EMT switch in murine mammary carcinoma in vitro and in vivo.

Authors:  Florian Wegwitz; Eva Lenfert; Daniela Gerstel; Lena von Ehrenstein; Julia Einhoff; Geske Schmidt; Matthew Logsdon; Johanna Brandner; Gisa Tiegs; Nicole Beauchemin; Christoph Wagener; Wolfgang Deppert; Andrea Kristina Horst
Journal:  Oncotarget       Date:  2016-09-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.